Cargando…

Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors

[Image: see text] Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferreira, Rafaela S., Simeonov, Anton, Jadhav, Ajit, Eidam, Oliv, Mott, Bryan T., Keiser, Michael J., McKerrow, James H., Maloney, David J., Irwin, John J., Shoichet, Brian K.
Formato: Texto
Lenguaje:English
Publicado: American Chemical Society 2010
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895358/
https://www.ncbi.nlm.nih.gov/pubmed/20540517
http://dx.doi.org/10.1021/jm100488w
_version_ 1782183255742611456
author Ferreira, Rafaela S.
Simeonov, Anton
Jadhav, Ajit
Eidam, Oliv
Mott, Bryan T.
Keiser, Michael J.
McKerrow, James H.
Maloney, David J.
Irwin, John J.
Shoichet, Brian K.
author_facet Ferreira, Rafaela S.
Simeonov, Anton
Jadhav, Ajit
Eidam, Oliv
Mott, Bryan T.
Keiser, Michael J.
McKerrow, James H.
Maloney, David J.
Irwin, John J.
Shoichet, Brian K.
author_sort Ferreira, Rafaela S.
collection PubMed
description [Image: see text] Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as false positives, yielding 146 well-behaved, competitive ligands. These fell into five chemotypes: two were prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches. Determination of an inhibitor/cruzain crystal structure and comparison of the high-scoring docking hits to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing molecules that are both predicted by docking and are HTS-active yields well-behaved molecules, relatively unobscured by the false-positives to which both techniques are individually prone.
format Text
id pubmed-2895358
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-28953582010-07-01 Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors Ferreira, Rafaela S. Simeonov, Anton Jadhav, Ajit Eidam, Oliv Mott, Bryan T. Keiser, Michael J. McKerrow, James H. Maloney, David J. Irwin, John J. Shoichet, Brian K. J Med Chem [Image: see text] Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as false positives, yielding 146 well-behaved, competitive ligands. These fell into five chemotypes: two were prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches. Determination of an inhibitor/cruzain crystal structure and comparison of the high-scoring docking hits to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing molecules that are both predicted by docking and are HTS-active yields well-behaved molecules, relatively unobscured by the false-positives to which both techniques are individually prone. American Chemical Society 2010-06-11 2010-07-08 /pmc/articles/PMC2895358/ /pubmed/20540517 http://dx.doi.org/10.1021/jm100488w Text en Copyright © 2010 American Chemical Society http://pubs.acs.org This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org.
spellingShingle Ferreira, Rafaela S.
Simeonov, Anton
Jadhav, Ajit
Eidam, Oliv
Mott, Bryan T.
Keiser, Michael J.
McKerrow, James H.
Maloney, David J.
Irwin, John J.
Shoichet, Brian K.
Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
title Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
title_full Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
title_fullStr Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
title_full_unstemmed Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
title_short Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors
title_sort complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895358/
https://www.ncbi.nlm.nih.gov/pubmed/20540517
http://dx.doi.org/10.1021/jm100488w
work_keys_str_mv AT ferreirarafaelas complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT simeonovanton complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT jadhavajit complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT eidamoliv complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT mottbryant complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT keisermichaelj complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT mckerrowjamesh complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT maloneydavidj complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT irwinjohnj complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors
AT shoichetbriank complementaritybetweenadockingandahighthroughputscreenindiscoveringnewcruzaininhibitors